Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 11/20 | 0.57 |
| ▸ | PPARA | Q07869 | 9/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.57 |
| ▸ | PPARD | Q03181 | 5/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | MME | P08473 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10077534 | 0.85 | PPARA (0.75) | PPARGPPARAEPHX2PPARD | |
| SCHEMBL28021287 | 0.85 | PPARA (0.75) | PPARGPPARAEPHX2PPARD | |
| SCHEMBL6379983 | 0.80 | CYP1A2 (0.59) | PPARGPPARAEPHX2PPARDCYP1A2 | |
| SCHEMBL3876493 | 0.80 | CYP1A2 (0.59) | PPARGPPARAEPHX2PPARDCYP1A2 | |
| SCHEMBL3661382 | 0.80 | CYP1A2 (0.59) | PPARGPPARAEPHX2PPARDCYP1A2 | |
| SCHEMBL11529738 | 0.80 | CYP1A2 (0.59) | PPARGPPARAEPHX2PPARDCYP1A2 | |
| SCHEMBL6941118 | 0.80 | KCNH2 (0.46) | PPARGPPARAPPARD | |
| SCHEMBL6941123 | 0.80 | KCNH2 (0.46) | PPARGPPARAPPARD | |
| SCHEMBL265514 | 0.80 | CYP1A2 (0.83) | PPARGPPARAPPARDCYP1A2MME | |
| SCHEMBL265063 | 0.80 | CYP1A2 (0.83) | PPARGPPARAPPARDCYP1A2MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8815935-B2 | Inhibitors of protein prenyltransferases | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-08-26 | — | — | US | disclosed |
| US-20130102639-A1 | INHIBITORS OF PROTEIN PRENYLTRANSFERASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-04-25 | — | — | US | disclosed |
| WO-2006098554-A1 | NOVEL COMPOUNDS, ISOMER THEREOF OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | AMOREPACIFIC CORPORATION (KR) | 2006-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130102639-A1 | INHIBITORS OF PROTEIN PRENYLTRANSFERASES | RABGGTA, FNTA, RABGGTB | PPARG 2042/4885PPARA 2747/4885EPHX2 2534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.